Physician profile
Mina Devine
NPI 1023539954
$3,721.42
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,185 · 2022: $1,536.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,930.87 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $369.25 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $285.18 | 2021-2022 | |
| Alkermes, INC. | $285.03 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $239.08 | 2021 | |
| Lundbeck LLC | $230.24 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $140.51 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $113.88 | 2021-2022 | |
| Indivior INC. | $28.24 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $26.27 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.60 | 2021 | |
| Noven Therapeutics, LLC | $24.62 | 2021 | |
| Neurocrine Biosciences, INC. | $22.65 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.